- Home
- UNCY vs MNOV Comparison
UNCY vs MNOV Comparison
Compare UNCY & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- MNOV
- Stock Information
- Founded
- UNCY 2016
- MNOV 2000
- Country
- UNCY United States
- MNOV United States
- Employees
- UNCY N/A
- MNOV N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- MNOV Health Care
- Exchange
- UNCY Nasdaq
- MNOV Nasdaq
- Market Cap
- UNCY 71.8M
- MNOV 76.5M
- IPO Year
- UNCY 2021
- MNOV 2005
- Fundamental
- Price
- UNCY $0.62
- MNOV $1.49
- Analyst Decision
- UNCY Strong Buy
- MNOV Strong Buy
- Analyst Count
- UNCY 3
- MNOV 1
- Target Price
- UNCY $5.50
- MNOV $9.00
- AVG Volume (30 Days)
- UNCY 510.7K
- MNOV 8.4K
- Earning Date
- UNCY 05-16-2025
- MNOV 05-16-2025
- Dividend Yield
- UNCY N/A
- MNOV N/A
- EPS Growth
- UNCY N/A
- MNOV N/A
- EPS
- UNCY N/A
- MNOV N/A
- Revenue
- UNCY N/A
- MNOV N/A
- Revenue This Year
- UNCY N/A
- MNOV N/A
- Revenue Next Year
- UNCY $1,502.84
- MNOV N/A
- P/E Ratio
- UNCY N/A
- MNOV N/A
- Revenue Growth
- UNCY N/A
- MNOV N/A
- 52 Week Low
- UNCY $0.20
- MNOV $1.12
- 52 Week High
- UNCY $1.16
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- UNCY 51.83
- MNOV 50.64
- Support Level
- UNCY $0.59
- MNOV $1.46
- Resistance Level
- UNCY $0.66
- MNOV $1.55
- Average True Range (ATR)
- UNCY 0.03
- MNOV 0.06
- MACD
- UNCY -0.00
- MNOV 0.00
- Stochastic Oscillator
- UNCY 40.05
- MNOV 44.44
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.